Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1990 Aug;62(2):275-6.
doi: 10.1038/bjc.1990.276.

Aromatase inhibition in advanced prostatic cancer: preliminary communication

R J Shearer  1 , J H Davies, M Dowsett, P R Malone, A Hedley, D Cunningham, R C Coombes
Affiliations
Free PMC article
Clinical Trial

Aromatase inhibition in advanced prostatic cancer: preliminary communication

R J Shearer et al. Br J Cancer. 1990 Aug.
Free PMC article

Abstract

We report the results of the first use of a steroidal aromatase inhibitor, 4-hydroxyandrostenedione (4-OHA, CGP 32349), in the palliation of patients with advanced, hormone resistant, prostatic cancer. Twelve of 19 patients (63%), who had relapsed following castration and other therapies, gained significant pain relief following weekly intramuscular injections of 4-OHA. Five patients (31%) experienced a transient 'tumour flare', represented by an increase in bone pain soon after commencing treatment. The mechanism of action of 4-OHA in palliating patients with advanced prostatic cancer is obscure at present, but may represent an important new treatment modality which may lead to greater insight into prostatic biology.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Trans Am Assoc Genitourin Surg. 1966;58:54-62 - PubMed
    1. Invest Urol. 1979 May;16(6):409-20 - PubMed
    1. Steroids. 1981 Dec;38(6):693-702 - PubMed
    1. J Steroid Biochem. 1982 Jul;17(1):119-20 - PubMed
    1. J Urol. 1983 Jan;129(1):51-5 - PubMed

Publication types